NCI-H358 is a tumorigenic cell line that was established in 1981 from the bronchiole tissue of a male with bronchioalveolar carcinoma. NCI-H358 cells display adherent cultural properties in vitro and an epithelial morphology. NCI-H358 produces lung surfactant associated protein A (SP-A) and expresses the RNA of SP-A. NCI-H358 cells are suitable transfection hosts, and Altogen Biosystems offers a NCI-H358 transfection reagent to transfect NCI-H358 cells. The NCI-H358 cell line can be used to study lung cancer and develop therapeutics.
Altogen Biosystems is a global producer and custom research organization for the pharmaceutical industry. Biological products and other goods include ELISA testing, optimization of preclinical research, stable transfection of cells, IND applications and more. Dedicated to helping researchers with state-of-the-art and efficient services, Altogen Biosystems strives to further modern clinical techniques. Visit the Altogen Biosystems website for lung xenograft models and related tools for preclinical drug testing.